$PRVCF has established a wholly owned subsidiary in Brisbane, Queensland, Australia to bolster their research and development interests. The Australian team which will be led by Dr. Maher Khaled, the Chief Executive Officer will work closely with Dr. Harry Parekh, PreveCeutical’s Chief Research Officer, to advance the company’s therapeutic pipeline. The office will provide access for regular engagement with commercial partners on other ventures that PreveCeutical is pursuing in the region.